FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 573 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February January 18, 2022 Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... July 7, 2020 Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in... July 16, 2025 Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... June 17, 2024 Load more HOT NEWS A Penny for Your Thoughts ΤΙ ΕΙΝΑΙ Is Proton Therapy Safer than Traditional Radiation? Ahead of a Key Meeting of EU Health Ministers, ESMO Calls...
